KMO and Huntington disease: In the HD mouse model, inhibition of KMO preserved synapses, mitigated microglia activation, and improved survival [156]; SzR-72 [N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline2-carboxamide hydrochloride], a KYNA analog, was reported to improve hypolocomotion, increase weight, prevent striatal neurons atrophy, and increase survival [157].